



PRESS RELEASE 2024-03-26

AcuCort's study to be published in an international scientific journal

AcuCort AB has been informed that an article regarding the company's survey study on treatment preferences among Swedish patients with acute allergic reactions will be published in the scientific journal World Allergy Organization Journal.

AcuCort is working to increase awareness of the oral film Zeqmelit®, with a planned launch at pharmacies in the Nordic countries during the summer. The scientific journal World Allergy Organization Journal, targeting allergists, allergy patient associations, and other relevant groups, has announced that an article on AcuCort's survey study will be published soon. The report underlying the article is titled "Disease Burden and Unmet Needs in Acute Allergic Reactions - A Patient Perspective".

"It's a significant recognition for the treatment that AcuCort's study on allergy patients is being addressed by a well-respected scientific journal reaching a large portion of our direct target audience. We look forward to increasing awareness of patients' need for an oral film in acute allergic reactions. The timing is also perfect as the launch of Zeqmelit® is planned for this summer," says Jonas Jönmark, CEO of AcuCort.

As previously communicated, the results from the study show, among other things, that 72 percent of the 426-person patient group would prefer an oral film over tablet treatment in severe allergic reactions. Additionally, 24 percent reported difficulties swallowing their allergy medication during a severe allergic reaction.

"AcuCort has concrete scientific data showing that our oral film Zeqmelit® is perceived as a faster and smoother medication than tablet treatments in severe allergic reactions," says Jonas Jönmark.

The survey study encompasses a total of 426 patients who have answered questions about their allergies and how they value the available treatment options. Initially, just over 100 patients were to be included in the study, but the significant interest in participating and the engagement among allergy sufferers led to the expansion of the study, ultimately including 426 respondents.

Summary of study results*

- 72 percent of patients responded that they would prefer an oral film over tablet treatment in case of a severe allergic reaction.
 - 24 percent of patients responded that they had experienced difficulties swallowing their allergy medication during a severe allergic reaction.
 - 68 percent of patients responded that they had at some point needed to seek emergency medical care for a severe allergic reaction.
 - 41 percent of patients responded that they had at some point feared for their life during a severe allergic reaction.
-

**Study results were published on September 22, 2022.*

For further information:

Jonas Jönmark, CEO AcuCort AB

Tel: +46 70 3655400

Email: jonas.jonmark@acucort.se

About AcuCort AB (publ)

AcuCort has developed and is commercializing Zeqmelit[®], a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit[®] is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.